^
    1m
    Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial. (PubMed, Lancet Oncol)
    These data demonstrate that targeting HRD yields promising outcomes in stage III, HER2-negative, HRD breast cancer and that intensified chemotherapy with autologous stem cell rescue does not provide any advantage over state-of-the-art chemotherapy plus olaparib.
    Clinical • P3 data • Journal • BRCA Biomarker • PARP Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • HRD
    |
    Lynparza (olaparib) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • thiotepa • Neulasta (pegfilgrastim)
    1m
    Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma (clinicaltrials.gov)
    P2, N=174, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Jan 2028 --> Feb 2027
    Trial completion date
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • mesna • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    2ms
    Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas (clinicaltrials.gov)
    P1, N=20, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: Apr 2026 --> Dec 2025
    Enrollment open • Trial initiation date
    |
    doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    2ms
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Apr 2026 --> Sep 2026
    Trial initiation date
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)
    2ms
    Pegfilgrastim versus filgrastim for chemo-mobilized stem cell collection in multiple myeloma: A retrospective real-world study. (PubMed, Cancer Treat Res Commun)
    Both PEG and FIL demonstrate equivalent efficacy for stem cell mobilization in MM. PEG offers superior efficiency by shortening duration and reducing sessions without increasing the total economic burden.
    Retrospective data • Journal • Real-world evidence
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide • Neulasta (pegfilgrastim)
    2ms
    EA8192: Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (clinicaltrials.gov)
    P2/3, N=131, Recruiting, National Cancer Institute (NCI) | N=249 --> 131
    Enrollment change
    |
    MSI (Microsatellite instability) • CD4 (CD4 Molecule)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • doxorubicin hydrochloride • methotrexate • vinblastine • Neulasta (pegfilgrastim) • methotrexate IV • Neupogen (filgrastim)
    2ms
    High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    cytarabine • etoposide IV • carmustine • melphalan • Neulasta (pegfilgrastim) • vadacabtagene leraleucel (JCAR015)
    2ms
    Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study. (PubMed, J Clin Oncol)
    Neoadjuvant ddMVAC plus durvalumab demonstrated encouraging pCR rates, favorable early survival outcomes, and manageable safety profile. Adding tremelimumab provides similar pCR but worse toxicity. These results support further study of ddMVAC plus durvalumab as a neoadjuvant chemoimmunotherapy strategy for localized MIBC, to be evaluated in comparative trials within an evolving perioperative treatment landscape.
    P1/2 data • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 underexpression • PD-L1 negative
    |
    cisplatin • Imfinzi (durvalumab) • doxorubicin hydrochloride • Imjudo (tremelimumab-actl) • methotrexate • vinblastine • Neulasta (pegfilgrastim)
    3ms
    GIM2: Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer (clinicaltrials.gov)
    P3, N=2000, Active, not recruiting, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | Trial completion date: Dec 2025 --> Dec 2027
    Trial completion date
    |
    paclitaxel • 5-fluorouracil • cyclophosphamide • epirubicin • Neulasta (pegfilgrastim)
    3ms
    S0533: Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    Avastin (bevacizumab) • cisplatin • docetaxel • etoposide IV • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    3ms
    CA2440012: Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy (2025-522400-24-00)
    P2/3, N=207, Recruiting, Bristol-Myers Squibb Services Unlimited Company
    New P2/3 trial
    |
    cisplatin • carboplatin • gemcitabine • izalontamab brengitecan (BL-B01D1) • izalontamab (SI-B001) • Neulasta (pegfilgrastim)
    4ms
    GCT1184-05: Study to assess the efficacy and safety of Rina-S in participants with non-small cell lung cancer (2025-522107-18-00)
    P1/2, N=34, Not yet recruiting, Genmab A/S
    New P1/2 trial
    |
    Neulasta (pegfilgrastim) • Rina-S (rinatabart sesutecan)